Eton Pharmaceuticals Inc (ETON) - Net Assets
Based on the latest financial reports, Eton Pharmaceuticals Inc (ETON) has net assets worth $46.59 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($115.81 Million) and total liabilities ($69.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Eton Pharmaceuticals Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $46.59 Million |
| % of Total Assets | 40.23% |
| Annual Growth Rate | 10.08% |
| 5-Year Change | 48.35% |
| 10-Year Change | N/A |
| Growth Volatility | 50.37 |
Eton Pharmaceuticals Inc - Net Assets Trend (2017–2025)
This chart illustrates how Eton Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ETON stock market capitalisation.
Annual Net Assets for Eton Pharmaceuticals Inc (2017–2025)
The table below shows the annual net assets of Eton Pharmaceuticals Inc from 2017 to 2025. Also explore Eton Pharmaceuticals Inc net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $26.15 Million | +7.07% |
| 2024-12-31 | $24.43 Million | +57.83% |
| 2023-12-31 | $15.48 Million | +18.34% |
| 2022-12-31 | $13.08 Million | -25.82% |
| 2021-12-31 | $17.63 Million | +12.56% |
| 2020-12-31 | $15.66 Million | +48.46% |
| 2019-12-31 | $10.55 Million | -59.89% |
| 2018-12-31 | $26.30 Million | +116.84% |
| 2017-12-31 | $12.13 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eton Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10385500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $27.00K | 0.10% |
| Other Components | $138.62 Million | 530.02% |
| Total Equity | $26.15 Million | 100.00% |
Eton Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Eton Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tecnoglass Inc
NYSE:TGLS
|
$1.59 Billion |
|
Yangling Metron New Material Co Ltd
SHE:300861
|
$1.59 Billion |
|
CIE Automotive India Limited
NSE:CIEINDIA
|
$1.59 Billion |
|
C3 Ai Inc
NYSE:AI
|
$1.59 Billion |
|
Hangzhou Shunwang Tech
SHE:300113
|
$1.59 Billion |
|
Henan Lingrui Pharmaceutical Co Ltd
SHG:600285
|
$1.59 Billion |
|
Guizhou Aviation Technical Development Co Ltd
SHG:688239
|
$1.58 Billion |
|
Hansol Chemica
KO:014680
|
$1.58 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eton Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 24,428,000 to 26,154,000, a change of 1,726,000 (7.1%).
- Net loss of 4,601,000 reduced equity.
- Other factors increased equity by 6,327,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.60 Million | -17.59% |
| Other Changes | $6.33 Million | +24.19% |
| Total Change | $- | 7.07% |
Book Value vs Market Value Analysis
This analysis compares Eton Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 57.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 79.88x to 57.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.69 | $55.50 | x |
| 2018-12-31 | $4.10 | $55.50 | x |
| 2019-12-31 | $0.59 | $55.50 | x |
| 2020-12-31 | $0.75 | $55.50 | x |
| 2021-12-31 | $0.70 | $55.50 | x |
| 2022-12-31 | $0.52 | $55.50 | x |
| 2023-12-31 | $0.60 | $55.50 | x |
| 2024-12-31 | $0.94 | $55.50 | x |
| 2025-12-31 | $0.97 | $55.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eton Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.75%
- • Asset Turnover: 0.87x
- • Equity Multiplier: 3.52x
- Recent ROE (-17.59%) is above the historical average (-64.33%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -58.99% | 0.00% | 0.00x | 1.11x | $-8.37 Million |
| 2018 | -48.44% | 0.00% | 0.00x | 1.08x | $-15.37 Million |
| 2019 | -173.65% | -1910.32% | 0.06x | 1.62x | $-19.38 Million |
| 2020 | -178.57% | -71717.95% | 0.00x | 1.68x | $-29.54 Million |
| 2021 | -11.09% | -8.95% | 0.79x | 1.56x | $-3.72 Million |
| 2022 | -68.98% | -42.45% | 0.85x | 1.91x | $-10.33 Million |
| 2023 | -6.05% | -2.96% | 1.00x | 2.05x | $-2.48 Million |
| 2024 | -15.65% | -9.80% | 0.51x | 3.12x | $-6.27 Million |
| 2025 | -17.59% | -5.75% | 0.87x | 3.52x | $-7.22 Million |
Industry Comparison
This section compares Eton Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $270,352,957
- Average return on equity (ROE) among peers: -49.78%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eton Pharmaceuticals Inc (ETON) | $46.59 Million | -58.99% | 1.49x | $1.59 Billion |
| Aurora Cannabis Inc (ACB) | $1.56 Billion | 4.60% | 0.21x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $-148.25 Million | 0.00% | 0.00x | $133.55 Million |
| Akanda Corp (AKAN) | $-5.03 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $394.76 Million | -70.84% | 0.95x | $245.30 Million |
| Alkermes Plc (ALKS) | $18.84 Million | -398.98% | 9.71x | $7.28 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-66.72 Million | 0.00% | 0.00x | $3.58 Billion |
| Amphastar P (AMPH) | $295.51 Million | -0.94% | 0.32x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $356.74 Million | 25.53% | 10.23x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $208.93 Million | -62.22% | 17.18x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $85.19 Million | 5.07% | 0.51x | $278.50 Million |
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for … Read more